ClinicalTrials.gg
RecruitingNCT06898177Updated Jun 16, 2026

Development and Testing of a Mobile App to Scale Delivery of Cognitive-behavioral Therapy for Avoidant/Restrictive Food Intake Disorder

An interventional study of mCBT-AR in Avoidant/Restrictive Food Intake Disorder (ARFID), sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Avoidant Restrictive Food Intake Disorder with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Avoidant Restrictive Food Intake Disorder · United States.

Planned enrollment
6th of 18
60 · median 38
Started
2026
with 2 others
No phase
17 of 23
5 open now
Registered
20th of 23
by date
Lead sponsor
5 of 23
Massachusetts General Hospital

Among the 23 studies in Avoidant Restrictive Food Intake Disorder with a site in United States, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2026, is one of 17 with no phase, and was the 20th registered.

Avoidant Restrictive Food Intake Disorder

41 studies on the registry are indexed under Avoidant Restrictive Food Intake Disorder; 12 are open to participants now.

Browse Avoidant Restrictive Food Intake Disorder studies →

Open to participants now

7 of the 23 studies in Avoidant Restrictive Food Intake Disorder with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Avoidant Restrictive Food Intake Disorder studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Avoidant Restrictive Food Intake Disorder with a site in United States, or all of them as a file.
02

Study summary

Avoidant/restrictive food intake disorder (ARFID) is a serious and impairing eating disorder - occurring in up to 4% of adults - for which most individuals do not have access to treatment. The proposed study aims to develop and test a mobile app to scale delivery of cognitive-behavioral therapy for ARFID. Knowledge gained will contribute to the development of a clinically accessible, scalable, inexpensive treatment for ARFID, a highly impairing disorder for which there are significant barriers to care access.

03

Conditions studied

  • Avoidant/Restrictive Food Intake Disorder (ARFID)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Current avoidant/restrictive food intake disorder based on criteria
  2. Must not have completed face-to-face CBT-AR at the Eating Disorders Clinical and Research Program at Massachusetts General Hospital
  3. Ability to speak, write, and understand English
  4. Residence in the United States
  5. Access to an internet-connected smartphone device

Exclusion criteria

Exclusion Criteria:

  1. Underweight status (i.e., \< 18.5 kg/m2)
  2. Complete lack of oral intake or dependence on supplemental feeding
  3. Feeding or eating disorder other than ARFID
  4. Any comorbid disorder that would require attention beyond the study treatment

6. Medical instability requiring inpatient care according to the American Psychiatric Association 2023 treatment guidelines for eating disorders 7. Medical history of intellectual disability 8. Illiteracy

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    mCBT-AR

    Behavioral: mCBT-AR

  • No intervention
    Usual care

Interventions

  • BehavioralmCBT-AR

    mCBT-AR is an 8-week virtual treatment for avoidant/restrictive food intake disorder delivered via mobile application

06

What researchers measure

Primary outcomes

  1. Pica, ARFID, and Rumination Disorder Interview - ARFID Questionnaire (PARDI-AR-Q)

    The PARDI-AR-Q is a 32-item self-report measure based on the Pica, ARFID, and Rumination Disorder Interview that assesses ARFID diagnostic criteria and the presence and severity of each ARFID profile. Severity scores for each profile range from 0-6, with higher scores indicating greater severity.

    Time frame: Change from baseline (assessed at study entry) to final session, which occurs an average of eight weeks after baseline (measured at weekly study treatment sessions)

  2. Food Neophobia Scale (FNS)

    The Food Neophobia Scale is a 6-item measure that measures reluctance to try new foods. Scores range from 7-42. Higher scores on the FNS are indicative of greater behavioral responses to novel foods.

    Time frame: Change from baseline (assessed at study entry) to final session, which occurs an average of eight weeks after baseline (measured at weekly study treatment sessions)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2030, 47 months after the start.

Of 16 interventional studies with no phase under Avoidant Restrictive Food Intake Disorder, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 43. This study's planned 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 27, 2025
StartActual
Apr 13, 2026
Primary completionEst.
Apr 1, 2030
CompletionEst.
Apr 1, 2030
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06898177
Responsible party
Paraskevi E. Kambanis (Clinical Psychologist, Massachusetts General Hospital) — Principal investigator
First posted
Mar 27, 2025
Start date
Apr 13, 2026
Primary completion
Apr 1, 2030 (estimated)
Completion
Apr 1, 2030 (estimated)
Last update
Jun 16, 2026

Study contacts

Paraskevi Kambanis, PhD
Contact
pkambanis@mgh.harvard.edu
617-724-0799
Jonathan Xiang, BS
Contact
jxiang2@mgh.harvard.edu

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion